Financials
Financial year 2025
Worth noting
- A loss two years in a row.
Gross margin
€ 0
▼ 100% vs 2024
Profit
Caution€ -9.6 million
▲ 18% vs 2024
Debts
Low€ 7.3 million
▲ 46% vs 2024
AgomAb Therapeutics from Antwerpen, company number BE0674527310, closed financial year 2025 with a result of € -9.6 million after tax. For that financial year AgomAb Therapeutics recorded a gross margin of € 0 and equity of € 244.1 million. Compared with financial year 2024, the result moved from € -11.7 million to € -9.6 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 23, 2026.
What happened at AgomAb Therapeutics?
What happened at AgomAb Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Colin Bond stepped down as director. NBB
- David Epstein stepped down as director. NBB
- Angelika Martha Jahreis stepped down as director. NBB
- Felice Verduyn - van Weegen stepped down as director. NBB
- Tim Knotnerus stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 9.6 million. Source: NBB ↗
- Ohad Hammer stepped down as director. NBB
- Xiaoming Fang stepped down as director. NBB
In short
From € 6.5 million loss in 2021 to € 9.6 million loss in 2025.
On average € 96,900 of value added per employee in 2024.
Pays suppliers within 108 days on average.
A new publication or filing at AgomAb Therapeutics? We notify you, reason included.
Follow AgomAb TherapeuticsNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
It owns 100% of Agomab US Inc. and 100% of Agomab Spain SLU itself.
Directors
According to the 2025 annual accounts
Angelika Martha Jahreis
Director
since 2023 · until 2029
Tim Knotnerus
Managing director
since 2021 · until 2027
Ohad Hammer
Director
since 2019 · until 2026
Felice Verduyn - van Weegen
Director
since 2023 · until 2029
Colin Bond
Director
since 2024 · until 2030
Xiaoming Fang
Director
since 2023 · until 2026
David Epstein
Director
since 2024 · until 2030
Establishments
Establishment units
Physical locations of this company
Posthoflei 1 box 6
2600 Antwerpen
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
Details
- Company number
- 0674.527.310
- VAT number
- BE 0674.527.310
- Registered office
- Posthoflei 1 bus 6, 2600 Antwerpen
- Names & denominations
- AgomAb Therapeutics
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 13 April 2017
- Peppol
- Active · Active since 5 Mar 2026
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overige technische testen en toetsen
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied